ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Human medicines European public assessment report (EPAR): Exelon, rivastigmine, Dementia,Alzheimer Disease,Parkinson Disease, Date of authorisation: 11/05/1998, Revision: 37, Status: Authorised
Case Medical Research
◽
10.31525/cmr-3ae9e7
◽
2018
◽
Author(s):
Keyword(s):
Alzheimer Disease
◽
Parkinson Disease
◽
Assessment Report
◽
European Public
◽
European Public Assessment Report
Download Full-text
Related Documents
Cited By
References
Human medicines European public assessment report (EPAR): Rivastigmine Hexal, rivastigmine, Dementia,Alzheimer Disease,Parkinson Disease, Date of authorisation: 11/12/2009, Revision: 10, Status: Authorised
Case Medical Research
◽
10.31525/cmr-1930425
◽
2019
◽
Author(s):
Keyword(s):
Alzheimer Disease
◽
Parkinson Disease
◽
Assessment Report
◽
European Public
◽
European Public Assessment Report
Download Full-text
Human medicines European public assessment report (EPAR): Rivastigmine Sandoz, rivastigmine, Dementia,Alzheimer Disease,Parkinson Disease, Date of authorisation: 10/12/2009, Revision: 11, Status: Authorised
Case Medical Research
◽
10.31525/cmr-587204
◽
2018
◽
Author(s):
Keyword(s):
Alzheimer Disease
◽
Parkinson Disease
◽
Assessment Report
◽
European Public
◽
European Public Assessment Report
Download Full-text
Human medicines European public assessment report (EPAR): Rivastigmine Sandoz, rivastigmine, Dementia,Alzheimer Disease,Parkinson Disease, Date of authorisation: 10/12/2009, Revision: 11, Status: Authorised
Case Medical Research
◽
10.31525/cmr-559118
◽
2018
◽
Author(s):
Keyword(s):
Alzheimer Disease
◽
Parkinson Disease
◽
Assessment Report
◽
European Public
◽
European Public Assessment Report
Download Full-text
Human medicines European public assessment report (EPAR): Prometax, rivastigmine, Alzheimer Disease,Parkinson Disease,Dementia, Date of authorisation: 03/12/1998, Revision: 35, Status: Authorised
Case Medical Research
◽
10.31525/cmr-559115
◽
2018
◽
Author(s):
Keyword(s):
Alzheimer Disease
◽
Parkinson Disease
◽
Assessment Report
◽
European Public
◽
European Public Assessment Report
Download Full-text
Human medicines European public assessment report (EPAR): DaTSCAN, ioflupane (123l), Tomography, Emission-Computed, Single-Photon,Lewy Body Disease,Parkinson Disease,Alzheimer Disease, Date of authorisation: 27/07/2000, Revision: 21, Status: Authorised
Case Medical Research
◽
10.31525/cmr-1891668
◽
2019
◽
Author(s):
Keyword(s):
Alzheimer Disease
◽
Parkinson Disease
◽
Lewy Body
◽
Single Photon
◽
Lewy Body Disease
◽
Assessment Report
◽
Emission Computed
◽
European Public
◽
European Public Assessment Report
Download Full-text
Human medicines European public assessment report (EPAR): Prometax, rivastigmine, Alzheimer Disease,Parkinson Disease,Dementia, Date of authorisation: 03/12/1998, Revision: 35, Status: Authorised
Case Medical Research
◽
10.31525/cmr-587193
◽
2018
◽
Author(s):
Keyword(s):
Alzheimer Disease
◽
Parkinson Disease
◽
Assessment Report
◽
European Public
◽
European Public Assessment Report
Download Full-text
Human medicines European public assessment report (EPAR): Rivastigmine 1 A Pharma, rivastigmine, Alzheimer Disease,Dementia,Parkinson Disease, Date of authorisation: 10/12/2009, Revision: 9, Status: Authorised
Case Medical Research
◽
10.31525/cmr-3996d5
◽
2018
◽
Author(s):
Keyword(s):
Alzheimer Disease
◽
Parkinson Disease
◽
Assessment Report
◽
European Public
◽
European Public Assessment Report
Download Full-text
Human medicines European public assessment report (EPAR): Exelon, rivastigmine, Dementia,Alzheimer Disease,Parkinson Disease, Date of authorisation: 11/05/1998, Revision: 37, Status: Authorised
Case Medical Research
◽
10.31525/cmr-58723a
◽
2018
◽
Cited By ~ 1
Author(s):
Keyword(s):
Alzheimer Disease
◽
Parkinson Disease
◽
Assessment Report
◽
European Public
◽
European Public Assessment Report
Download Full-text
Human medicines European public assessment report (EPAR): Memantine Mylan, memantine, Alzheimer Disease, Date of authorisation: 21/04/2013, Revision: 4, Status: Authorised
Case Medical Research
◽
10.31525/cmr-3996cc
◽
2018
◽
Author(s):
Keyword(s):
Alzheimer Disease
◽
Assessment Report
◽
European Public
◽
European Public Assessment Report
Download Full-text
Human medicines European public assessment report (EPAR): Pramipexole Teva, pramipexole, Parkinson Disease, Date of authorisation: 18/12/2008, Revision: 19, Status: Authorised
Case Medical Research
◽
10.31525/cmr-1e4edd3
◽
2019
◽
Author(s):
Keyword(s):
Parkinson Disease
◽
Assessment Report
◽
European Public
◽
European Public Assessment Report
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close